share_log

Invivyd | 8-K: Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

Invivyd | 8-K: Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

Invivyd | 8-K:Invivyd公布2024年第一季度财务业绩和近期业务亮点
美股sec公告 ·  05/10 04:16
牛牛AI助手已提取核心信息
On May 9, 2024, Invivyd, Inc., a biopharmaceutical company, announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent business highlights. The company reported a cash and cash equivalents balance of $189.4 million and expects to end the year with at least $75 million, based on projected net product revenue of $150-$200 million. Invivyd launched PEMGARDA in the U.S. for COVID-19 pre-exposure prophylaxis in certain immunocompromised adults and adolescents, following its emergency use authorization by the FDA on March 22, 2024. The company also received reimbursement codes from CMS, covering approximately half of the target population for PEMGARDA. Additionally, Invivyd plans to submit an EUA application for COVID-19 treatment in certain immunocompromised individuals, based on FDA feedback. The company...Show More
On May 9, 2024, Invivyd, Inc., a biopharmaceutical company, announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent business highlights. The company reported a cash and cash equivalents balance of $189.4 million and expects to end the year with at least $75 million, based on projected net product revenue of $150-$200 million. Invivyd launched PEMGARDA in the U.S. for COVID-19 pre-exposure prophylaxis in certain immunocompromised adults and adolescents, following its emergency use authorization by the FDA on March 22, 2024. The company also received reimbursement codes from CMS, covering approximately half of the target population for PEMGARDA. Additionally, Invivyd plans to submit an EUA application for COVID-19 treatment in certain immunocompromised individuals, based on FDA feedback. The company is advancing its next monoclonal antibody candidate, VYD2311, engineered with advanced technologies for variant monitoring and antibody engineering. Research and development expenses for the quarter were $31.2 million, and selling, general, and administrative expenses were $14.9 million. The net loss for the quarter was $43.5 million, with a net loss per share of $0.38. Invivyd will host a conference call to discuss these updates.
2024年5月9日,生物制药公司Invivyd, Inc. 公布了截至2024年3月31日的第一季度财务业绩,并提供了近期业务亮点的最新情况。该公司报告的现金及现金等价物余额为1.894亿美元,预计年底净产品收入为1.5亿至2亿美元,预计年底将达到至少7500万美元。继美国食品药品管理局于2024年3月22日批准紧急使用后,Invivyd在美国推出了PEMGARDA,用于对某些免疫功能低下的成年人和青少年进行 COVID-19 暴露前预防。该公司还收到了CMS的报销代码,涵盖了PEMGARDA目标人群的大约一半。此外,Invivyd 计划根据美国食品药品管理局的反馈,向某些免疫功能低下的人提交...展开全部
2024年5月9日,生物制药公司Invivyd, Inc. 公布了截至2024年3月31日的第一季度财务业绩,并提供了近期业务亮点的最新情况。该公司报告的现金及现金等价物余额为1.894亿美元,预计年底净产品收入为1.5亿至2亿美元,预计年底将达到至少7500万美元。继美国食品药品管理局于2024年3月22日批准紧急使用后,Invivyd在美国推出了PEMGARDA,用于对某些免疫功能低下的成年人和青少年进行 COVID-19 暴露前预防。该公司还收到了CMS的报销代码,涵盖了PEMGARDA目标人群的大约一半。此外,Invivyd 计划根据美国食品药品管理局的反馈,向某些免疫功能低下的人提交 COVID-19 治疗的 EUA 申请。该公司正在推进其下一个候选单克隆抗体 VYD2311,该抗体采用先进的变异监测和抗体工程技术进行设计。该季度的研发费用为3,120万美元,销售、一般和管理费用为1,490万美元。该季度的净亏损为4,350万美元,每股净亏损0.38美元。Invivyd 将主持电话会议,讨论这些更新。

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成,只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。